3 directors have bought £50k of Bioventix shares across 4 disclosed dealings since April 2026.
| 24 Jun 2026 | Bruce Hiscock — Chief Financial Officer | £9,600 |
| 10 Apr 2026 | Ian Nicholson — Non-Executive Chairman | £18,480 |
| 8 Apr 2026 | Peter Harrison — Chief Executive Officer | £19,702 |
| 2 Apr 2026 | Bruce Hiscock — Chief Financial Officer | £2,044 |
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.